GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InhaleRx Ltd (ASX:IRX) » Definitions » Net Intangibles Purchase And Sale

InhaleRx (ASX:IRX) Net Intangibles Purchase And Sale : A$0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is InhaleRx Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

InhaleRx's net Intangibles purchase and sale for the six months ended in Dec. 2024 was A$0.00 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00 Mil.

InhaleRx Net Intangibles Purchase And Sale Historical Data

The historical data trend for InhaleRx's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InhaleRx Net Intangibles Purchase And Sale Chart

InhaleRx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Intangibles Purchase And Sale
Get a 7-Day Free Trial Premium Member Only - -0.01 - - -

InhaleRx Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

InhaleRx Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InhaleRx Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of InhaleRx's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

InhaleRx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InhaleRx Ltd (ASX:IRX) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
ASX:ADRDA ASX:UCM ASX:CBL ASX:HMD ASX:AT1 ASX:UBI ASX:OSL ASX:CDX ASX:LDX ASX:NTI ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM STE PODD
Traded in Other Exchanges
N/A
Address
C/- Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Website
https://www.inhalerx.com.au
InhaleRx Ltd is an Australian biotechnology company specialising in precision medicine delivered through inhalation. Its novel drug device combinations target the treatment of BTcP and PD to help improve the quality of life of sufferers of these diseases. The medications are being developed to be delivered via a pressurised metered dose inhaler (pMDI) in a fixed dose, providing a convenient and effective mode of administration. The company's clinical pipeline comprises IRX211, a THC-based synthetic cannabinoid derived drug (dronabinol) delivered via a pMDI in a fixed dose designed to provide rapid onset analgesia for patients suffering from acute episodic bursts of breakthrough pain; and IRX616a, for the treatment of panic disorders.

InhaleRx Headlines

No Headlines